

Litteraturlista

- Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earle CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. *Value Health* 2005;8(2):157-67.
- Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. *Arch Neurol* 1982;39:739.
- Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. *Clin Neuropharmacol* 1987;10:69-79.
- Allen R. Dopamine and iron in the Pathophysiology of restless legs syndrome (RLS). *Sleep Med* 2004;5:385-391.
- Allen RP, Barker PB, Wehrl F, Song HK, Early CJ. MRI measurement of brain iron in patients with restless legs syndrome. *Neurology* 2001;56:263-265.
- Allen RP, Picchetti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. *Sleep Med* 2003;4:101-119.
- Allen RP. Iron, RLS and blood donations. *Sleep Med* 2004;5:113-114.
- Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ et al. Restless legs syndrome prevalence and impact: REST general population study. *Arch Intern Med* 2005;165(13):1286-92.
- Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. *Sleep Med* 2009
- Baker WL, White CM, Coleman CI. Effects of non-ergot dopamine agonists on symptoms of restless legs syndrome. *Ann Fam Med* 2008;6(3):253-62.
- Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. *Mayo Clin Proc* 2006;81(1):17-27.
- Chadhuri KR, Forbes A, Grosset D, et al. Diagnosing restless legs syndrome (RLS) in the primary care. *Curr Med Res Opin* 2004;20:1785-1795.
- Early CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. *Sleep Med* 2004;5:231-235.
- Ekbom K, Ulfberg J. Restless legs syndrome. *Journ Internal Med* 2009;266:419-431
- Ekbom K, Leissner L, Olsson JE, Widner H. Restless legs – vanligt sjukdomstillstånd som ofta missas. Möjligheter till framgångsrik behandling finns idag. *Läkartidningen* 2006; 103(4):207-11.
- Ekbom KA. [Restless legs in blood donors.], *Sven Läkartidn* 1956;53:3098-3103.
- Ekbom KA. Growing pains and restless legs. *Acta Paediatr Scand* 1975;64:264-266.
- Ekbom KA. Restless legs syndrome. *Acta Med Scand* 1945;158:4-122.
- Ekbom KA. Restless legs syndrome. *Neurology* 1960;10:868-873.
- Ekbom KA. Restless legs syndrome. *Neurology* 1960;1960:868.
- Ekbom KA. Restless legs: a clinical study. *Acta Med Scand Suppl* 1945;158:1-123.
- Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri KR, Sohr M, Verri D et al. Effect of pramipexol on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. *Sleep Med* 2008;9(8):874-81.

Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. *Sleep Med* 2004;5:5-6.

Garcia-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel WH, Hening W, Paulus W, Rye D, Walters AS, Winkelmann J. Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine – International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. *Sleep Med* 2007;8(207):520-530.

Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Cailoway MO et al. Effects of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. *Pharmacotherapy* 2008;29(3):255-62.

Happe S, Trenkwalder C. Role of dopamine receptor agonists in the treatment of uremic restless legs syndrome. *CNS Drugs* 2004, 18:27-36.

Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. *Measuring functioning and well-being: The Medical outcomes study approach*. Durham, NC: Duke University Press; 1992. P 235-59.

Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. *Sleep Med* 2004;5(3):237-46.

Hu J. Acupuncture treatment of restless legs syndrome. *J Tradit Chin Med* 2001;21:312-316.

Kohnen R, Benes H, Heinrich CR, Kurella B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS QoL) questionnaire. *Mov Dis* 2002;17(Suppl 5):743.

Kushida CA, Geyer J, Tolson JM, Asgharian A. Patient and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome. *Clin Neuropharmacol* 2008;31(5):281-6.

Leissner L, Grote L, Hedner J, Ulfberg J. Iron sucrose (Venofer®) reduces symptoms of Restless Legs Syndrome (RLS); A randomised double-blind, placebo controlled comparison 2004

Levchenko A, Montplaisir JY, Dube MP, et al. The 14q restless legs syndrome locus in the French Canadian population. *Ann Neurol* 2004;55:887-891.

Läkemedelsverket. Läkemedelsbehandling av restless legs syndrome – RLS – Ny rekommendation. Information från Läkemedelsverket nr 3, 2009.

Mallon L, Broman JE, Hetta J. Restless legs symptoms with sleepiness in relation to mortality: 20 year follow-up study of a middle-aged Swedish population. *Psych and Clin Neurosci* 2008;62:457-63.

Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. *Sleep Med* 2004;5:305-308.

Montplaisir J, Boucher S, Poirer G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome : a study of 133 patients diagnosed with new standard criteria. *Mov Disord* 1997;12:61-65.

Nordlander NB. Therapy in restless legs. *Acta Med Scand* 1953;145:453-457.

Oertel WH, Stiasny-Kolster K, Bergtholdt B, Hallström Y, Albo J, Leissner L et al. Efficacy of pramipexole in restless legs syndrome: a six week, multicenter, randomized, double-blind study (effect –RLS study). *Mov Disord* 2007;22(2):213-9.

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B et al. Efficiency of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six week dose finding trial in Europe. *Sleep Med* 2008;9(3):228-39.

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Trenkwalder C et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. *Sleep Med* 2008;9(8):865-73.

- O'Keefe ST. Iron deficiency with normal ferritin levels in restless legs syndrome. *Sleep Med* 2005;In Press.
- Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study – The PRELUDE study. *Sleep Med* 2006;7:407-417.
- Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. *Neurology The Lancet* 2006;5:878-886.
- Schapira AH. Restless legs syndrome: an update on treatment options. *Drugs* 2004;64:149-158.
- Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. *Mayo Clin Proc* 2004;79:916-922.
- Trenkwalder C, Wetter TC, Stiasny K, Clarenbach P. Restless legs syndrome und periodic limb movements in sleep. *Nervenarzt* 2001;72:425-436.
- Trenkwalder C, Winkelmann J. Pathophysiologie des Restless-legs-Syndroms: Aktueller Stand der Forschung. *Nervenarzt* 2001;72:100-107.
- Trenkwalder C. Behandlung des Restless Legs Syndroms: Die therapeutische Zukunft gehört den Dopaminagonisten. *Neurol & Psych* 2004;6:25-33.
- Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. *Mov Disord* 2008; 23(16):2267-302.
- Trenkwalder C, Stiasny K, Pollmächer T, Wetter T, Schwarz J, Kohlen R et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. *Sleep* 1995;18(8):681-8.
- Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. *Lancet Neurol* 2008;7(7):595-604.
- Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P et al. Ropinirole in the treatment of restless legs syndrome: result from the TREAT RLS 1 study, a 12 week, randomized, placebo-controlled study in 10 European countries. *J Neurol Neurosurg Psychiatry* 2004;75(1):92-7.
- Ulfberg J, Nyström B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. *Mov Disord* 2001;16:1159-1163.
- Ulfberg J, Nyström B, Carter N, Edling C. Restless Legs Syndrome among working-aged women. *Eur Neurol* 2001;46:17-19.
- Ulfberg J, Nyström B, Carter N, Edling C. Restless legs syndrome in blood donors. *Sleep Med* 2004;5:115-118.
- Von Scheele C. Levodopa in restless legs. *The Lancet* 1986;2:426-427.
- Von Spiczak S, Whone C, Hammers A, et al. The role of opioids in restless legs syndrome: an [11C] diprenorphine PET study. *Brain* 2005.
- Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. *Sleep Med* 2003;4(2):121-32.
- Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirol is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. *Mov Disord* 2004;19(12):1414-23.
- Willis T. *The London Practice of Physick*. London: Basset & Crooke, 1685.

Winkelmann JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ et al. Efficacy and safety of pramipexole in restless legs syndrome. *Neurology* 2006;67(6):1034-9.